The short version of anti-doping fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2025-09-07 and is reviewed periodically as new material appears.
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.
Detection of SR9009 in biological samples usually relies on liquid chromatography coupled to tandem mass spectrometry. This approach separates the compound from matrix components and identifies it by mass transitions. Because SR9009 can undergo metabolism, laboratories often look for both parent drug and specific metabolites. Sample preparation may involve protein precipitation or solid-phase extraction. Method validation examines sensitivity, carryover, and interference from related substances, and reference standards are required for accurate calibration.
Storage recommendations for SR9009 reference material typically specify a freezer at -20 °C or lower, with protection from moisture and light. Repeated freeze-thaw cycles can degrade small molecules and introduce variability. Stock solutions in dimethyl sulfoxide are often aliquoted to avoid repeated handling. Stability studies may examine degradation under heat, humidity, and light exposure. The compound's thiophene and nitro groups can participate in reactions that alter analytical signals over time, so such changes affect quantitative results.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C20H24ClN3O4S | Derived from published structure. |
| Molecular weight | 437.94 g/mol | Calculated value. |
| Appearance | White to off-white solid | Typical for purified research samples. |
| Solubility | DMSO, ethanol; low in water | Class: poorly water-soluble. |
| Typical storage | -20 °C, desiccated, protected from light | Limits degradation. |
Research interest in SR9009 grew from studies of circadian biology and metabolic disease. Preclinical reports describe effects on exercise capacity, muscle metabolism, and blood lipid levels in rodents, but these findings come from controlled laboratory settings. The compound has low oral bioavailability in animals, which limits systemic exposure after swallowing. Investigators often use injected routes in experiments to achieve measurable plasma concentrations. Human clinical data are sparse, no approved therapeutic product exists, and whether animal effects translate to humans remains an open question.
Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.
SR9009 is not approved as a medicine by major regulatory agencies. It is commonly sold as a research chemical, a category that may fall outside customary drug approval and quality rules. In sports, the World Anti-Doping Agency lists SR9009 as a prohibited substance. Athletes who use it can face sanctions if it is detected in a sample. Legal status varies by country, and importation may be restricted. Enforcement practices differ across borders.
Detection of SR9009 in biological samples usually employs liquid chromatography coupled with tandem mass spectrometry. This method can identify the parent compound and sometimes metabolites in urine or blood. Because exposure can be low and clearance may be rapid, sample timing and limits of detection matter. Laboratories validate assays for sensitivity and specificity. Results are interpreted alongside chain-of-custody and quality-control records. Urine is the common matrix for anti-doping analysis, while blood may be used in research settings.
Handling recommendations for SR9009 in a laboratory setting include storing the solid at low temperature, protected from light and moisture. The compound is often dissolved in dimethyl sulfoxide or ethanol for experiments. Solutions should be prepared with appropriate personal protective equipment and disposed of according to local rules. Stability data for long-term storage are limited, so stock solutions are typically kept cold and used within defined periods. Records of preparation date and concentration support reproducibility.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms and metabolic gene expression. In laboratory experiments, SR9009 binds these receptors and alters transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. It is not a naturally occurring compound and has no approved therapeutic use. Research interest stems from its ability to modify energy metabolism in cells and animal models.
In rodent studies, SR9009 has been reported to increase mitochondrial content in skeletal muscle and improve exercise endurance under some conditions. These findings led to popular descriptions such as an exercise mimetic, although that term oversimplifies the biology. Effects vary by dose, timing, tissue, and model. The compound's influence on circadian pathways means that time of administration can matter in experiments. Whether similar metabolic changes occur in humans remains largely unexplored in controlled published trials.
Pharmacokinetic data for SR9009 are limited in published literature. Some reports indicate low oral bioavailability and rapid clearance in animals, which complicates interpretation of exposure and effect. Researchers often use injected routes in preclinical work to achieve measurable systemic levels. Analytical studies rely on mass spectrometry to detect the parent compound and its metabolites. Questions about tissue distribution, active metabolites, and long-term consequences remain open. Species differences in metabolism can affect observed half-life and target engagement.
=== Salt Concentration === Most enzymes cannot tolerate extremely high salt concentrations. The ions interfere with the weak ionic bonds of proteins. Typical enzymes are active in salt concentrations of 1-500 mM. As usual there are exceptions such as the halophilic algae and halophilic bacteria.
===== COX-1 inhibitors ===== Potent antiplatelet medications that irreversibly inhibit the activity of cyclooxygenase (COX), an enzyme involved in the synthesis of thromboxane A2 (TXA2) which is responsible for platelet activation and aggregation. The major member of this class is aspirin. Some common adverse effects associated with this class of medications include bronchospasm and gastrointestinal disturbances such as dyspepsia and nausea. Therefore, this class of drugs should be used with caution in patients with a history of peptic ulcer disease.
He added that efforts were ongoing to secure and defend remote and hard-to-reach areas. Also, on 25 March, two TTP militants were killed in a CTD operation in Tank District. On 27 March, BBC Dari citing satellite imagery, reported that Pakistan had fenced off 32 square kilometers of land in Paktika province, raising speculation that it may have occupied the area. According to BBC Dari, no visible fence line could be seen on 20 March, but by 23 March satellite imagery showed a new fence that had been built 12 kilometers inside Afghan territory. BBC Dari also reported that, after the completion of the first fence line, a second fence was built at the mouth of the same area, more than 13.5 kilometers inside Afghan territory. However, the Afghan Ministry of Defense said that Mali Khan Siddiq, the deputy army chief of the Afghan armed forces, had visited border areas in Paktika and dismissed claims that Pakistani forces had occupied Terwa district as false propaganda. Naseer Ahmad Faiq, Afghanistan's acting Permanent Representative to the UN, said that if reports of Pakistan seizing Afghan territory were true, they would amount to "naked aggression" and should be condemned in the strongest terms. He added that any occupation of Afghan land would be illegal under international law, violate the UN Charter and Afghanistan's territorial integrity, and that Afghanistan's sovereignty was non-negotiable.
Sources: en.wikipedia.org
Scarborough is represented by six ridings for the provincial government and Federal government. Municipal riding boundaries were harmonized within the City of Toronto to match the provincial boundaries in 1999 through provincial legislation called The Fewer Municipal Politicians Act of 1999. This took effect on December 1, 2000. Ridings were represented by two councillors per riding until 2018 when the Government of Ontario reduced this to one councillor per riding. Scarborough now has six councillors.
Eddy stayed there for two years, from 1868 to 1870, teaching Wentworth with Quimby's unpublished essay, "Questions and Answers." She acknowledged that the manuscript was Quimby's, and spoke often of how she had promised to teach his healing method, which at the time she called Moral Science.
== Geometry == In coordination chemistry, a structure is first described by its coordination number, the number of ligands attached to the metal (more specifically, the number of donor atoms). Usually one can count the ligands attached, but sometimes even the counting can become ambiguous. Coordination numbers are normally between two and nine, but large numbers of ligands are not uncommon for the lanthanides and actinides. The number of bonds depends on the size, charge, and electron configuration of the metal ion and the ligands. Metal ions may have more than one coordination number. Typically the chemistry of transition metal complexes is dominated by interactions between s and p molecular orbitals of the donor-atoms in the ligands and the d orbitals of the metal ions. The s, p, and d orbitals of the metal can accommodate 18 electrons (see 18-Electron rule). The maximum coordination number for a certain metal is thus related to the electronic configuration of the metal ion (to be more specific, the number of empty orbitals) and to the ratio of the size of the ligands and the metal ion. Large metals and small ligands lead to high coordination numbers, e.g. [Mo(CN)8]4−. Small metals with large ligands lead to low coordination numbers, e.g. Pt[P(CMe3)]2. Due to their large size, lanthanides, actinides, and early transition metals tend to have high coordination numbers.
Springer's lab screened for such activity in cell line supernatants, purified and sequenced the protein, and found that stromal derived factor (SDF-1), previously defined as a growth factor for B cells, was a potent chemoattractant for both B and T cells. SDF-1 activated an orphan GPCR, later named CXCR4, which was also the co-receptor for T-cell-tropic HIV; SDF-1 further blocked infection of T cells by HIV. SDF-1 (CXCL12) is also a chemoattractant for CD34+ hematopoietic stem cells and regulates their movement from bone marrow to the bloodstream. Based on these discoveries, plerixafor (Mozobil) was developed as an antagonist of CXCR4 and is approved, in combination with filgrastim, for use in mobilizing hematopoietic stem cells in patients with multiple myeloma or non-Hodgkin lymphoma. In later retrospective discussion, Springer framed the three steps in leukocyte emigration into inflammatory sites as an “area code” model, emphasizing that each step requires a cognate receptor–ligand interaction and therefore provides multiple intervention points (selectins and ligands; GPCRs and ligands; integrins including LFA-1, α4β1, α4β7 and endothelial ligands). He argued that the size of the target space exceeded what could be pursued in an academic laboratory and helped motivate company formation.
Sources: en.wikipedia.org
SR9009 is a synthetic REV-ERB agonist used in laboratory research. It is not an approved drug, and its effects in humans are not well characterized. It is often sold as a research chemical under the name Stenabolic.
No. SR9009 targets the nuclear receptors REV-ERBα and REV-ERBβ, not the androgen receptor. This mechanism differs from selective androgen receptor modulators and from exercise mimetics that act on PPARδ.
Published evidence is mainly preclinical, using cell cultures and animal models. Controlled human trials are not well documented in the public literature. Claims about human performance or health effects therefore remain unsupported by robust clinical data.
Liquid chromatography-tandem mass spectrometry is a common approach. It can detect the parent compound and its metabolites in biological matrices.